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Abstract
IMPORTANCE Transcatheter aortic valve replacement (TAVR) has been shown to be a valid
alternative to surgical aortic valve replacement (SAVR) in patients at high operative risk with severe
aortic stenosis (AS). However, the evidence of the benefits and harms of TAVR in patients at low
operative risk is still scarce.
OBJECTIVE To compare the short-term andmidterm outcomes after TAVR and SAVR in low-risk
patients with AS.
DESIGN, SETTING, ANDPARTICIPANTS This retrospective comparative effectiveness cohort study
used data from the Nationwide Finnish Registry of Transcatheter and Surgical Aortic Valve
Replacement for Aortic Valve Stenosis of patients at low operative risk who underwent TAVR or SAVR
with a bioprosthesis for severe AS from January 1, 2008, to November 30, 2017. Low operative risk
was defined as a Society of Thoracic Surgeons Predicted Risk of Mortality score less than 3%without
other comorbidities of clinical relevance. One-to-one propensity score matching was performed to
adjust for baseline covariates between the TAVR and SAVR cohorts.
EXPOSURES Primary TAVR or SAVRwith a bioprosthesis for AS with or without associated coronary
revascularization.
MAINOUTCOMES ANDMEASURES The primary outcomes were 30-day and 3-year survival.
RESULTS Overall, 2841 patients (mean [SD] age, 74.0 [6.2] years; 1560 [54.9%]men) fulfilled the
inclusion criteria and were included in the analysis; TAVRwas performed in 325 patients and SAVR in
2516 patients. Propensity score matching produced 304 pairs with similar baseline characteristics.
Third-generation devices were used in 263 patients (86.5%) who underwent TAVR. Among these
matched pairs, 30-day mortality was 1.3% after TAVR and 3.6% after SAVR (P = .12). Three-year
survival was similar in the study cohorts (TAVR, 85.7%; SAVR, 87.7%; P = .45). Interaction tests found
no differences in terms of 3-year survival between the study cohorts in patients younger than vs
older than 80 years or in patients who received recent aortic valve prostheses vs those who did not.
(continued)
Key Points
Question Does transcatheter aortic
valve replacement achieve similar
results compared with surgical aortic
valve replacement in patients at low
operative risk with severe aortic
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effectiveness cohort study of 2841
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Abstract (continued)
CONCLUSIONSANDRELEVANCE Transcatheter aortic valve replacement usingmostly third-
generation devices achieved similar short- andmid-term survival comparedwith SAVR in low-risk pa-
tients. Further studies are needed to assess the long-termdurability of TAVRprostheses before extend-
ing their use to low-risk patients.
JAMANetwork Open. 2019;2(6):e195742.
Corrected on July 12, 2019. doi:10.1001/jamanetworkopen.2019.5742
Introduction
The development of transcatheter aortic valve replacement (TAVR) has made the treatment of
severe aortic stenosis (AS) feasible with similar short- andmid-term outcomes compared with
surgical aortic valve replacement (SAVR) in patients with high1-3 or intermediate4-6 operative risk.
Clinical practice has recently turned toward treating even low-risk patients with TAVR, and 3 recent
randomized clinical trials reported favorable short-term results with TAVR in these patients.7-9 The
Evolut Low Risk Trial7 documented a 2-year mortality of 4.5% after either TAVR or SAVR. The
PARTNER 3 Trial8 reported a 1-year mortality of 1.0% after TAVR and 2.5% after SAVR. The Nordic
Aortic Valve Intervention Trial (NOTION)9,10 randomized patients to receive TAVR or SAVR, and 82%
of the patients were at low risk for surgical operations, ie, Society of Thoracic Surgeons Predicted
Risk of Mortality (STS-PROM) score less than 4%. Similar outcomes were achieved in both TAVR and
SAVR treatment arms at 6 years.9,10 A 2018 study11 showed that transfemoral TAVR using mainly a
third-generation balloon-expandable TAVR device was associated with no deaths at 30 days
compared with 1.7% in a historical, propensity-matched SAVR cohort. However, the long-term
durability of TAVR prostheses in low-risk populations is questionable based on registry data, to our
knowledge.12 This leaves uncertainty whether TAVR is an acceptable treatment for low-risk patients.
The aim of this study was to compare the short-term andmidterm survival of low-risk patients
treated with TAVR and SAVR in a nationwide study.
Methods
StudyDesign and Participants
The Nationwide Finnish Registry of Transcatheter and Surgical Aortic Valve Replacement for Aortic
Valve Stenosis (FinnValve registry) is a study (ClinicalTrials.gov identifier, NCT03385915) that includes
retrospectively collected data from consecutive and unselected patients treated with TAVR or SAVR
with bioprostheses for AS from January 1, 2008, to November 30, 2017, at all 5 university hospitals in
Finland (Helsinki University Hospital, Helsinki, Finland; Kuopio University Hospital, Kuopio, Finland;
Oulu University Hospital, Oulu, Finland; Tampere University Hospital, Tampere, Finland; and Turku
University Hospital, Turku, Finland). The study followed the Strengthening the Reporting of
Observational Studies in Epidemiology (STROBE) reporting guideline. The study protocol was approved
by the institutional review boards of all participating centers. Informed consent was waived because
of the retrospective nature of this study. The inclusion criteria for study entry were age older than 18
years, previous primary aortic valve procedure with a bioprosthesis for AS with or without associated
regurgitation, and TAVR or SAVRwith or without associated coronary revascularization. The exclusion
criteria were any prior TAVR or surgical intervention on the aortic valve; a concomitantmajor procedure
on themitral valve, tricuspid valve, or ascending aorta; active endocarditis; or any procedure for isolated
aortic valve regurgitation. The operative risk of patients was stratified according to STS-PROM13 and
updated European System for Cardiac Operative Risk Evaluation (EuroSCORE II)14 scores. Exclusion
criteria included having an STS-PROM score of 3% or higher, undergoing an urgent or emergency
procedure, having previously undergone a cardiac surgical operation, being older than 85 years,
undergoing chronic dialysis, having a functioning kidney transplant, having severe frailty, having an
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active malignancy, having had a recent episode of acute heart failure, having a porcelain aorta, being
treatedwith oxygen therapy, having a left ventricular ejection fraction of 30%or below, having a severe
mitral valve regurgitation, or not having transfemoral access for TAVR (eFigure in the Supplement).
Data were retrospectively collected in a dedicated electronic case report form by cardiologists,
cardiac surgeons, and trained research nurses from December 1, 2017, to July 31, 2018, and
underwent robust checking of its completeness and quality. Data onmortality were retrieved from
the Finnish national registry Statistics Finland. Follow-up was considered complete for all patients,
but follow-up was truncated at hospital discharge for those not residing in Finland. Analyses were
conducted October 29, 2018, through November 7, 2018.
Baseline Risk Factors
Baseline variables were defined according to the EuroSCORE II criteria.14 Severe frailty was defined
as Geriatric Status Scale15 grades 2 and 3. Coronary artery disease (CAD) was defined as any stenosis
of 50%ormore of themain coronary branches. Recent acute heart failurewas defined as new-onset
or worsening of heart failure requiring hospital admission within 60 days prior to intervention.
OutcomeMeasures
The primary outcomeswere 30-day and 3-year survival. The secondary outcomeswere stroke, blood
transfusion, bleeding, resternotomy for bleeding, paravalvular regurgitation, new permanent
pacemaker implantation, acute kidney injury, renal replacement therapy, conversion to cardiac
surgical procedure, coronary artery occlusion, aortic dissection or rupture, major vascular
complication, atrial fibrillation, postoperative length of stay in the hospital where the procedure was
performed, and repeated aortic valve replacement.
Stroke andmajor vascular complications were defined according to the Valvular Academic
Research Consortium-2 criteria.16 Major bleeding was defined as EuropeanMulticenter Study on
Coronary Artery Bypass Grafting bleeding grades 2 or 3, ie, transfusion of more than 4 units of red
blood cells or resternotomy for excessive bleeding.17 In this study, the Valvular Academic Research
Consortium-2 definition of major and life-threatening bleeding was not applied because, unlike
patients undergoing TAVR, a significant decrease of hemoglobin level is observed in most patients
undergoing SAVR, and this does not always reflect a condition of major perioperative blood loss.
Acute kidney injury was defined according to the Kidney Disease: Improving Global Outcomes
classification criteria,18 ie, stage 1 is an increase in serum creatinine levels of at least 1.5-fold the
baseline level or a serum creatinine level increase of at least 0.3mg/dL (to convert tomicrograms per
liter, multiply by 88.4); stage 2 is an increase in serum creatinine level 2.0- to 2.9-fold the baseline;
and stage 3 is defined as an increase in serum creatinine concentration at least 3-fold the baseline
level or a serum creatinine concentration increase at least 4.0 mg/dL during the hospital stay or de
novo renal replacement therapy during the hospital stay.
Statistical Analysis
Statistical analysis was performed using SAS statistical software version 9.2 (SAS Institute) and SPSS
statistical software version 25.0 (IBM). Continuous variables are reported asmeans and SDs as well
as median and interquartile ranges, while categorical variables are reported as counts and
percentages. Mann-Whitney U test, Fisher exact test, and χ2 test were used for univariate analysis in
the unmatched population.Missing datawere not replaced. A propensity scorewas estimated using
a nonparsimonious logistic regression model, including age, sex, body mass index, hemoglobin,
estimated glomerular filtration rate, diabetes, stroke, transient ischemic attack, pulmonary disease,
extracardiac arteriopathy, New York Heart Association class 4 symptoms, left ventricular ejection
fraction of 50% or less, atrial fibrillation, pulmonary artery pressure, recent myocardial infarction,
CAD, left main coronary stenosis, number of diseased coronary arteries, moderate mitral valve
regurgitation, and prior pacemaker as covariates. One-to-one propensity score matching was
performed using the nearest-neighbor method and a caliper width of 0.2 of the SD of the logit of the
JAMANetworkOpen | Cardiology Transcatheter vs Surgical Aortic Valve Replacement Among Low-Risk Patients With Aortic Stenosis
JAMA Network Open. 2019;2(6):e195742. doi:10.1001/jamanetworkopen.2019.5742 (Reprinted) June 14, 2019 3/13
Downloaded From: https://jamanetwork.com/ by a Helsinki Univeristy Library User  on 10/21/2019
propensity score. Furthermore, 3 different propensity score–matching analyses were performed
addressing exact matching of patients older than 80 years, with CAD, and with selected valve
prostheses (ie, third-generation TAVR prostheses and their variants (ie, EvolutR, Sapien 3, ACURATE
neo, and Lotus) and selected SAVR prostheses and their variants with proven durability (ie, Trifecta,
Perimount).19 These matched data sets were used for interaction tests analyses. To evaluate the
balance between thematched groups, the t test for paired samples for continuous variables, the
McNemar test for dichotomous variables, and the analysis of the standardized differences after
matching were used. Standardized differences less than 0.10 were considered an acceptable
imbalance between the treatment groups. Early outcomes in the propensity score–matched cohorts
were evaluated using the t test for paired samples for continuous variables and the McNemar test
for dichotomous variables. These tests were used to evaluate any difference in the adverse events of
propensity score–matched pairs. Differences in the long-term survival of matched pairs were
evaluated using the Kaplan-Meier method with the Klein-Moeschberger stratified log-rank test. P
values were 2-tailed, and a P value less than .10 was considered statistically significant for interaction
tests of matched cohorts. A P value less than .05 was considered statistically significant for all the
other tests.
Results
The FinnValve registry includes data from 6463 patients who underwent primary TAVR or SAVRwith
a bioprosthesis for severe AS. Of these, 2841 patients (mean [SD] age, 74.0 [6.2] years; 1560 [54.9%]
men) fulfilled the inclusion criteria and were included in analysis (eFigure in the Supplement).
Surgical aortic valve replacement was performed in 2516 patients, and TAVRwas performed in 325
patients. A significant interinstitutional difference in the prevalence of low-risk patients undergoing
TAVRwas observed (Helsinki, 102 patients [11.0%]; Kuopio, 75 patients [18.7%]; Oulu, 74 patients
[13.2%]; Tampere, 20 patients [3.4%]; Turku, 54 patients [14.8%]; P < .001). Themean (SD)
follow-up of this series was 4.0 (2.7) years (TAVR cohort, 1.7 [1.4] years; SAVR cohort, 4.3 [2.7] years).
Characteristics andOutcomes of the Unmatched Cohorts
The baseline characteristics of the low-risk patients in the unmatched TAVR and SAVR groups are
shown in Table 1. Patients who underwent SAVRwere younger, more oftenmen, and had lower
STS-PROM and EuroSCORE II risk scores compared with patients in the TAVR cohort (Table 1). Before
matching, the prevalence of previous stroke, pulmonary disease, peripheral arteriopathy, atrial
fibrillation, andmitral regurgitation was higher in the TAVR cohort compared with the SAVR cohort.
Patients in the SAVR cohort had a higher prevalence of CAD andmore often underwent concomitant
revascularization.
In unmatched cohorts, 4 patients (1.2%) in the TAVR cohort and 50 patients (2.0%) in the SAVR
cohort died within 30 days (P = .52). Early outcomes of the unadjusted cohorts are presented in
Table 2. Three-year survival was lower for the TAVR cohort (85.5%) compared with the SAVR cohort
(92.0%), but the difference was not statistically significant (P = .20).
Characteristics andOutcomes of the Propensity Score–Matched Cohorts
Propensity score matching produced 304 pairs of patients with similar baseline characteristics
(Table 3). The standardized differences between groups were less than the prespecifiedmargin
indicating good balance of covariates. The rate of planned concomitant revascularization was lower
in the TAVR group compared with the SAVR group (6 patients [2.0%] vs 49 patients [16.1%];
P < .001). The prevalence of CAD (57 patients in each group [18.8%]) and the frequency of previous
percutaneous coronary intervention (TAVR, 51 patients [16.8%]; SAVR, 49 patients [16.1%]) were
similar between thematched cohorts. Selected, more recent prostheses were used for 263 patients
(86.5%) undergoing TAVR procedures and 150 patients (49.3%) undergoing SAVR procedures.
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Among thematched pairs, 30-daymortality included 4 patients (1.3%) after TAVR and 11
patients (3.6%) after SAVR (P = .12) (Table 4). Three-year survival was similar in the study cohorts
(85.7% vs 87.7% for TAVR and SAVR, respectively; P = .45) (Figure).
Patients who underwent TAVR had a shorter mean (SD) hospital stay (4.1 [3.2] days vs 7.9 [5.7]
days; P < .001) and lower rates of atrial fibrillation (92 patients [30.3%] vs 194 patients [63.4%];
P < .001), resternotomy for bleeding (1 patient [0.3%] vs 18 patients [5.9%]; P < .001), and European
Multicenter Study on Coronary Artery Bypass Grafting bleeding grades 2 or 3 (7 patients [2.3%] vs
51 patients [16.9%]; P < .001) compared with patients who underwent SAVR (Table 4). Two patients
Table 1. Characteristics of Unmatched PatientsWith LowOperative Risk Undergoing Transcatheter
or Surgical Aortic Valve Replacementa
Characteristic
No. (%)
Standardized Difference
(95% CI) P Value
TAVR
(n = 325)
SAVR
(n = 2516)
Age, y
Mean (SD) 78.1 (6.0) 73.4 (6.0)
0.77 (0.66 to 0.77) <.001
Median (IQR) 80.0 (75.7-82.1) 74.0 (69.9-77.7)
Men 153 (47.1) 1407 (55.9) 0.18 (0.06 to 0.29) .003
Body mass indexb
Mean (SD) 28.6 (5.1) 28.0 (4.7)
0.12 (0.01 to 0.24) .05
Median (IQR) 27.9 (24.7-31.9) 27.4 (24.6-30.8)
Hemoglobin, g/dLc
Mean (SD) 13.0 (1.5) 13.4 (1.3)
0.38 (0.27 to 0.50) <.001
Median (IQR) 13.1 (12.1-14.0) 13.6 (12.7-14.5)
eGFR, mL/min/1.73 m2c
Mean (SD) 76 (21) 80 (20)
0.20 (0.09 to 0.32) <.001
Median (IQR) 73 (62-88) 79 (66-92)
Diabetes 75 (23.1) 555 (22.1) 0.02 (−0.09 to 0.14) .68
Stroke 29 (8.9) 127 (5.0) 0.15 (0.04 to 0.27) .004
Transient ischemic attack 22 (6.8) 107 (4.3) 0.11 (−0.01 to 0.23) .04
Pulmonary disease 60 (18.5) 275 (10.9) 0.21 (0.10 to 0.33) <.001
Extracardiac arteriopathy 41 (12.6) 207 (8.2) 0.14 (0.03 to 0.26) .008
LVEF ≤50% 47 (14.5) 298 (11.8) 0.08 (−0.04 to 0.19) .18
Atrial fibrillation 118 (36.3) 457 (18.2) 0.42 (0.30 to 0.53) <.001
NYHA class 4 7 (2.2) 20 (0.8) 0.11 (−0.002 to 0.23) .02
SPAP, mm Hg
31-55 109 (33.5) 799 (31.8)
0.12 (0 to 0.23) .11
>55 18 (5.5) 86 (3.4)
Moderate mitral regurgitation 25 (7.7) 77 (3.1) 0.22 (0.10 to 0.33) <.001
Recent myocardial infarction 4 (1.2) 20 (0.8) 0.04 (−0.08 to 0.16) .42
Coronary artery disease 60 (18.5) 877 (34.9) 0.38 (0.26 to 0.49) <.001
Left main coronary stenosis 2 (0.6) 76 (3.0) 0.18 (0.07 to 0.30) .01
No. of diseased vessels
Mean (SD) 0.2 (0.5) 0.6 (0.9)
0.47 (0.36 to 0.59) <.001
Median (IQR) 0 (0) 0 (0-1.0)
Prior PCI 65 (20.0) 200 (7.9) 0.35 (0.24 to 0.47) <.001
Permanent pacemaker 24 (7.4) 90 (3.6) 0.17 (0.05 to 0.28) .001
Planned concomitant PCI
or CABG
9 (2.8) 812 (32.3) 0.84 (0.72 to 0.96) <.001
EuroSCORE II, %
Mean (SD) 2.6 (1.5) 2.1 (1.1)
0.42 (0.31 to 0.54) <.001
Median (IQR) 2.2 (1.7-3.2) 1.8 (1.3-2.6)
STS-PROM score, %
Mean (SD) 2.1 (0.5) 1.8 (0.6)
0.63 (0.51 to 0.74) <.001
Median (IQR) 2.2 (1.8-2.5) 1.7 (1.3-2.2)
Abbreviations: CABG, coronary artery bypass grafting;
eGFR, estimated glomerular filtration rate; EuroSCORE
II, updated European System for Cardiac Operative
Risk Evaluation; IQR, interquartile range; LVEF, left
ventricular ejection fraction; NYHA, New York Heart
Association functional classification; PCI,
percutaneous coronary intervention; SAVR, surgical
aortic valve replacement; SPAP, systolic pulmonary
artery pressure; STS-PROM, Society of Thoracic
Surgeons Predicted Risk of Mortality; TAVR,
transcatheter aortic valve replacement.
SI conversion factor: To convert hemoglobin to grams
per liter, multiply by 10.
a Clinical variables are according to the EuroSCORE II
definition criteria.
b Calculated as weight in kilograms divided by height
in meters squared.
c Calculated using the original Modification of Diet in
Renal Disease equation.
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in each cohort had coronary ostium occlusion, and conversion to cardiac surgical operations was
necessary for 3 patients in the TAVR cohort. Major vascular complications were more frequent in the
TAVR cohort than the SAVR cohort (27 patients [8.9%] vs 7 patients [2.3%]; P = .001), and patients
who received TAVR experienced higher rates of paravalvular regurgitation with SAVR (mild
regurgitation: TAVR, 46 patients [15.1%]; SAVR, 17 patients [5.6%]; moderate regurgitation: TAVR, 9
patients [3.0%]; SAVR, 2 patients [0.7%]; P < .001).
No significant difference was observed in the rates of stroke between the cohorts. There was a
higher rate of acute kidney injury in the SAVR cohort (15 patients [5.0%]) compared with the TAVR
cohort (6 patients [2.0%]), but the difference was not significant (P = .12). Permanent pacemaker
implantation was needed more often among patients who underwent TAVR than those who
underwent SAVR (29 patients [9.5%] vs 14 patients [4.6%]; P = .03).
The interaction test for type of procedure and CADwas statistically significant and
demonstrated unfavorable intermediate survival in patients with CADwho underwent SAVR (eTable
in the Supplement). Interaction tests found that survival in the TAVR cohort was similar to that of
the SAVR cohort for patients younger than vs older than 80 years (P for interaction = .23) and for
patients who received selected valve prostheses vs those who did not (P for interaction = .26)
(eTable in the Supplement).
Discussion
This nationwide study represents one of the largest studies of low-risk patients who underwent TAVR
or SAVR, to our knowledge.We found that short-term andmidtermmortality in low-risk patients was
low and similar after TAVR or SAVR, TAVRwas associatedwith shorter hospital stays and a favorable
safety profile in terms of major perioperative bleeding, and SAVR was associated with lower rates of
severe vascular complication, paravalvular regurgitation, and need of permanent pacemaker.
Table 2. Early Outcomes of Unmatched Low-Risk Patients Undergoing TAVR or SAVR
Outcome
No. (%)
P Value
TAVR
(n = 325)
SAVR
(n = 2516)
Deaths within 30 d 4 (1.2) 50 (2.0) .52
Conversion to cardiac surgery 3 (0.9) NA NA
Coronary ostium occlusion 2 (0.6) 9 (0.4) .36
Aortic dissection/rupture 2 (0.6) 19 (0.8) >.99
Major vascular complication 28 (8.6) 36 (1.4) <.001
Stroke 6 (1.8) 76 (3.0) .23
RBC transfusion, units
Mean (SD) 0.4 (1.2) 2.3 (3.3)
<.001
Median (IQR) 0 (0) 2.0 (0-3.0)
RBC transfusion >4 units 8 (2.5) 353 (14.2) <.001
Resternotomy for bleeding 1 (0.3) 190 (7.6) <.001
E-CABG bleeding grades 2-3 8 (2.5) 418 (16.8) <.001
KDIGO acute kidney injury grades 2-3 6 (1.9) 111 (4.4) .03
Renal replacement therapy 1 (0.3) 39 (1.6) .08
Paravalvular regurgitation
Mild 48 (14.8) 135 (5.4)
<.001Moderate 9 (2.8) 10 (0.4)
Severe 0 4 (0.2)
Atrial fibrillation 100 (30.8) 1330 (52.9) <.001
Permanent pacemaker 35 (10.8) 98 (3.9) <.001
Hospital stay, d
Mean (SD) 4.1 (3.2) 7.7 (5.7)
<.001
Median (IQR) 4.0 (2.0-5.0) 7.0 (5.0-8.0)
Abbreviations: E-CABG, European Coronary Artery
Bypass Grafting registry; IQR, interquartile range;
KDIGO, Kidney Disease: Improving Global Outcomes;
NA, not applicable; RBC, red blood cells; SAVR, surgical
aortic valve replacement; TAVR, transcatheter aortic
valve replacement.
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This study represents a nationwide practice demonstrating that from January 1, 2008, to
November 30, 2017, 325 of 2841 patients (11.4%) with AS and low operative risk were treated with
TAVR in Finland. Slightly lower proportions of low-risk patients during a similar time frame was
reported by Schymik et al.20 An STS-PROM score less than 3.0%was selected as the cutoff value for
Table 3. Characteristics of Propensity Score–Matched PatientsWith LowOperative RiskWhoUnderwent TAVR or SAVRa
Characteristic, No. (%)
TAVR
(n = 304)
SAVR
(n = 304)
Standardized Difference
(95% CI) P Value
Age, y
Mean (SD) 77.9 (6.0) 78.1 (4.8)
0.036 (−0.123 to 0.195) .95
Median (IQR) 79.8 (75.4 to 82.0) 79.0 (74.4-82.1)
Women 161 (53.0) 153 (50.3) 0.053 (−0.106 to 0.212) .57
Body mass indexb
Mean (SD) 28.5 (5.1) 28.7 (4.9)
0.028 (−0.131 to 0.187) .33
Median (IQR) 27.8 (24.7 to 31.9) 28.0 (24.8-31.6)
Hemoglobin, g/dL
Mean (SD) 13.1 (1.5) 13.0 (1.4)
0.04 (−0.12 to 0.20) .60
Median (IQR) 13.2 (12.1 to 14.0) 13.0 (12.1-13.9)
eGFR, mL/min/1.73 m2c
Mean (SD) 76 (21) 76 (20)
0.01 (−0.15 to 0.17) .95
Median (IQR) 73 (26) 74 (26)
Diabetes 68 (22.4) 68 (22.4) 0 (−0.16 to 0.16) >.99
Stroke 26 (8.6) 24 (7.9) 0.02 (−0.14 to 0.18) .89
Transient ischemic attack 20 (6.6) 19 (6.3) 0.01 (−0.15 to 0.20) >.99
Pulmonary disease 54 (17.8) 59 (19.4) 0.04 (−0.12 to 0.20) .68
Extracardiac arteriopathy 39 (12.8) 42 (13.8) 0.03 (−0.13 to 0.19) .81
LVEF ≤50% 41 (13.5) 40 (13.2) 0.01 (−0.15 to 0.17) >.99
Atrial fibrillation 107 (35.2) 105 (34.5) 0.01 (−0.15 to 0.17) .93
NYHA class 4 5 (1.6) 8 (2.6) 0.07 (−0.09 to 0.23) .58
SPAP, mm Hg
31-55 101 (33.2) 95 (31.3)
0.06 (−0.10 to 0.22) .12
>55 15 (4.9) 18 (5.9)
Moderate mitral regurgitation 20 (6.6) 19 (6.3) 0.04 (−0.12 to 0.20) .80
Recent myocardial infarction 3 (1.0) 2 (0.7) 0.09 (−0.07 to 0.24) >.99
Coronary artery disease 57 (18.8) 57 (18.8) 0 (−0.16 to 0.16) >.99
Left main coronary stenosis 2 (0.7) 5 (1.6) 0.09 (−0.07 to 0.25) .45
No. of diseased vessels
Mean (SD) 0.2 (0.6) 0.3 (0.6)
0.03 (−0.13 to 0.19) .92
Median (IQR) 0 (0) 0 (0)
Prior PCI 51 (16.8) 49 (16.1) 0.02 (−0.14 to 0.18) .91
Permanent pacemaker 21 (6.9) 15 (4.9) 0.08 (−0.08 to 0.24) .41
Planned concomitant PCI or CABG 6 (2.0) 49 (16.1) 0.51 (0.35 to 0.67) <.001
EuroSCORE II score, %
Mean (SD) 2.6 (1.4) 2.5 (1.3)
0.04 (−0.12 to 0.20) .65
Median (IQR) 2.2 (1.7 to 3.2) 2.2 (1.6 to 3.0)
STS-PROM score, %
Mean (SD) 2.1 (0.9) 2.1 (0.5)
0.03 (−0.14 to 0.18) .82
Median (IQR) 2.2 (1.7 to 2.5) 2.2 (1.7 to 2.6)
Abbreviations: CABG, coronary artery bypass grafting; eGFR, estimated glomerular
filtration rate; EuroSCORE-II, updated European System for Cardiac Operative Risk
Evaluation; IQR, interquartile range; LVEF, left ventricular ejection fraction; NYHA, New
York Heart Association functional classification; PCI, percutaneous coronary
intervention; SAVR, surgical aortic valve replacement; SPAP, systolic pulmonary artery
pressure; STS-PROM, Society of Thoracic Surgeons Predicted Risk of Mortality; TAVR,
transcatheter aortic valve replacement.
SI conversion factor: To convert hemoglobin to grams per liter, multiply by 10.
a Clinical variables are according to the EuroSCORE II definition criteria.
b Calculated as weight in kilograms divided by height in meters squared.
c Calculated using the original Modification of Diet in Renal Disease equation.
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low-risk patients, which is supported by earlier studies.10,21 Patients who have generally a higher
operative risk, such as patients older than 85 years with severe frailty and a recent acute heart failure
episode, were excluded, leaving a small proportion of patients with comorbidities.
Initially, TAVRwas indicated only for inoperable or high–operative risk patients, but accepted
clinical practice has expanded to perform TAVR in patients at lower operative risk7,8,22 and requires
more data on long-term outcomes in these populations. To our knowledge, the longest follow-up
data on similar survival after TAVR or SAVR extend 5 years for high-risk patients,1,3 while data on
intermediate survival among low-risk patients are limited.5,6,10 Despite the short-term results
Table 4. Early Outcomes in Propensity Score–Matched Low-Risk Patients Undergoing TAVR and SAVR
Outcome
No. (%)
P Value
TAVR
(n = 304)
SAVR
(n = 304)
Deaths at 30 d 4 (1.3) 11 (3.6) .12
Conversion to cardiac surgery 3 (1.0) NA NA
Coronary ostium occlusion 2 (0.7) 2 (0.7) >.99
Aortic dissection or rupture 2 (0.7) 5 (1.6) .45
Major vascular complication 27 (8.9) 7 (2.3) .001
Stroke 6 (2.0) 16 (5.3) .12
RBC transfusion, units
Mean (SD) 0.4 (1.2) 2.5 (2.9)
<.001
Median (IQR) 0 (0) 2.0 (0-4.0)
RBC transfusion >4 units 7 (2.3) 46 (15.1) <.001
Resternotomy for bleeding 1 (0.3) 18 (5.9) <.001
E-CABG bleeding grades 2-3 7 (2.3) 51 (16.9) <.001
KDIGO acute kidney injury grades 2-3 6 (2.0) 15 (5.0) .12
Renal replacement therapy 1 (0.3) 5 (1.7) .22
Paravalvular regurgitation
Mild 46 (15.1) 17 (5.6)
<.001Moderate 9 (3.0) 2 (0.7)
Severe 0 0
Atrial fibrillation 92 (30.3) 194 (63.4) <.001
Permanent pacemaker 29 (9.5) 14 (4.6) .03
Hospital stay, d
Mean (SD) 4.1 (3.3) 7.9 (5.2)
<.001
Median (IQR) 3.0 (2.0-5.0) 7.0 (5.0-9.0)
Abbreviations: E-CABG, European Coronary Artery
Bypass Grafting registry; IQR, interquartile range;
KDIGO, Kidney Disease: Improving Global Outcomes;
NA, not applicable; RBC, red blood cells; SAVR, surgical
aortic valve replacement; TAVR, transcatheter aortic
valve replacement.
Figure. Kaplan-Meier Estimate of Survival in Low-Risk PatientsWith Aortic StenosisWhoUnderwent
Transcatheter (TAVR) or Surgical Aortic Valve Replacement (SAVR)
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documented with TAVR compared with SAVR in low-risk patients from two 2019 randomized clinical
trials,7,8 there are limited data on themidterm and long-term outcomes after TAVR in low-risk
patients. Our data suggest that similar and excellent survival can be expected 3 years after TAVR
(85.7%) and SAVR (87.7%) in patients deemed to have low operative risk. Indeed, the 3-year survival
of patients who underwent TAVRwas higher than reported in a low-risk series from the 2016
Observational Study of Effectiveness of SAVR-TAVI Procedures for Severe Aortic Stenosis Treatment
(OBSERVANT),12 in which the TAVR cohort had inferior midterm survival compared with the SAVR
cohort. However, OBSERVANT gathered data from 2010 to 2012 with limited operator experience
and using only second-generation TAVR devices.12 The higher rate of significant paravalvular
regurgitationmight have been negatively associated with long-term outcomes observed in
OBSERVANT, a phenomenon well documented in other studies.3,4,23 Indications for TAVR expanded
to include low-risk patients only in recent years; therefore, 86.5% of low-risk patients in the
FinnValve registry who underwent TAVR received third-generation TAVR devices and were treated
by more experienced operators. Minimal-risk patients in the TAVIK registry20 had a lower 2-year
survival after TAVR (90.9%) compared with SAVR (95.7%; P = .001), a difference that was likely
associated with older age in the TAVR cohort. The NOTION trial randomizedmainly low-risk patients
(mean STS-PROM score, 3%; mean EuroSCORE II score, 2%) to receive TAVR or SAVR and
demonstrated similar survival rates at 6 years (57.5% vs 62.3%), despite a 15% rate of moderate
aortic regurgitation in the TAVR arm.9,10
To our knowledge, this study is one of few providing 3-year follow-up survival after TAVR and
SAVR in low-risk patients with AS. Numerically higher 30-day mortality was observed after SAVR in
the overall (50 of 2516 patients [2.0%]) and matched (11 of 304 patients [3.6%]) populations. It is
worth noting that 30-day mortality after TAVR was lower than predicted by the STS-PROM and
EuroSCORE II scores in the overall (4 of 325 patients [1.2%]) andmatched (4 of 304 patients [1.3%])
populations. The same was not observed in the SAVR cohort. These findings are similar to those of
previous studies in low-risk populations, which reported in-hospital 30-daymortality of 1% to 2% in
both TAVR and SAVR populations.11,20,24 A 2018 study byWaksman et al11 found nomortality at 30
days among low-risk patients who underwent TAVR. However, the study by Waksman et al11
consisted of patients much younger than other studies. Overall, current data suggest that very low
operativemortality can be expectedwhen treating low-risk patients older than 70 years with TAVR or
SAVR techniques. Indeed, in the 2019 Placement of Aortic Transcatheter Valves (PARTNER) 3 trial,8
30-daymortality was 0.5% after TAVR and 1.3% after SAVR, and in the Evolut Low Risk trial,7 30-day
mortality was 0.4% after TAVR and 1.1% after SAVR.
Nearly half of patients treated for AS have concomitant CAD.25 In our study of selected low-risk
patients, less than 1 of 5 patients had significant CAD. The prevalence of CAD and history of
percutaneous coronary intervention were comparable in the study cohorts. However, only 15% of
patients with CAD undergoing TAVR underwent any planned coronary revascularization, while 93%
of patients with CAD undergoing SAVR underwent a concomitant revascularization. This reflects the
contemporary practice of accomplishing revascularization concomitantly with SAVR if CAD is
detected by a preoperative coronary angiography, as supported by the 2017 European Society of
Cardiology and European Association for Cardio-Thoracic Surgery guidelines26 and the 2014
American Heart Association and American College of Cardiology guideline.27 Patients undergoing
combined SAVR and coronary surgery procedures are potentially exposed to a higher risk of early
mortality, most likely owing to CAD itself as well as to prolonged intraoperative myocardial ischemia.
In these patients, cardiac surgeons are prone to perform coronary artery bypass grafting and
administer antegrade cardioplegia through vein grafts to avoid suboptimal myocardial protection
during prolonged cardiopulmonary bypass and to decrease the risk of possible ischemic
complications early after SAVR. The risk of myocardial ischemia is lower after TAVR because of the
minimally invasive nature of this treatment, which does not require the use of cardiac arrest during
cardiopulmonary bypass. It is worth noting that leaving CAD untreated during SAVR impairs long-
term survival regardless of the severity of CAD.28 In the present study, we observed that concomitant
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CADwas associated with worse outcomes in patients undergoing SAVR (eTable in the Supplement).
It is also possible that increased operativemortality in the SAVR cohort was partly owing to a higher
proportion of combined procedures, although the revascularization rate was performed in only 16%
of the matched patients in the SAVR cohort. The association of concomitant CAD with long-term
mortality after TAVR is controversial,25,29 and the indication of percutaneous coronary intervention
prior to or during TAVR is commonly discussed before valve intervention. The severity of CAD and
success of revascularizationmay have a role in survival after TAVR, and these components have to be
considered during decisionmaking.30 Interpreting the results of studies about AS and coexisting CAD
becomesmore difficult when considering the hemodynamic severity of CAD,31,32 and hopefully the
ongoing Percutaneous Coronary Intervention Prior to Transcatheter Aortic Valve Implantation
ACTIVATION (ISRCTN75836930) and NOTION-3 (NCT03058627) trials will provide conclusive data
on the potential benefits of percutaneous coronary intervention during TAVR.
The distribution of periprocedural complications in our study was typical compared with
another low-risk study byWitberg et al.33 Bleeding and atrial fibrillation were less frequent in the
TAVR cohort, and less vascular complications and new permanent pacemaker implantations were
observed in the SAVR cohort. Higher rates of acute kidney injury and stroke were observed after
SAVR, but severe intraprocedural complications were infrequent. Major bleeding events were
significantly higher in the SAVR cohort than the TAVR cohort.
Limitations
Themain limitation of this study is its retrospective nature. Second, the definition of low risk was
based on a cutoff value of 3% for operative mortality as estimated by the STS-PROM scoring system
and by excluding patients deemed at increased risk because of significant comorbidities. Despite
these inclusion criteria, it is possible that some patients included or excluded from this analysis were
incorrectly classified. Third, comparative analysis of the study cohorts was based on propensity score
matching, and its results are potentially biased by unmeasured confounders despite well-balanced
covariates. Fourth, the relatively small size of thematched study cohorts may affect the reliability of
these results. Fifth, the limited length of follow-up of patients with low operative risk prevented
more conclusive results on the durability of TAVR in this patient population.
Conclusions
This nationwide registry analysis found that TAVR usingmostly third-generation devices achieved
similar early and intermediate survival compared with SAVR in low-risk patients. Before extending
the use of TAVR to low-risk patients, further studies are needed to assess the long-term durability of
transcatheter aortic valve prostheses.
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